Literature DB >> 7628440

Detailed analysis of the IL-5-IL-5R alpha interaction: characterization of crucial residues on the ligand and the receptor.

S Cornelis1, G Plaetinck, R Devos, J Van der Heyden, J Tavernier, C J Sanderson, Y Guisez, W Fiers.   

Abstract

The receptor for interleukin-5 (IL-5) is composed of two different subunits. The IL-5 receptor alpha (IL-5R alpha) is required for ligand-specific binding while association with the beta-chain results in increased binding affinity. Murine IL-5 (mIL-5) has similar activity on human and murine cells, whereas human IL-5 (hIL-5) has marginal activity on murine cells. We found that the combined substitution of K84 and N108 on hIL-5 by their respective murine counterpart yields a molecule which is as potent as mIL-5 for growth stimulation of a murine cell line. Since the unidirectional species specificity is due only to the interaction with the IL-5R alpha subunit, we have used chimeric IL-5R alpha molecules to define regions of hIL-5R alpha involved in species-specific hIL-5 ligand binding. We found that this property is largely determined by the NH2-terminal module of hIL-5R alpha, and detailed analysis defined D56 and to a lesser extent E58 as important for binding. Moreover, two additional residues, D55 and Y57, were identified by alanine scanning mutagenesis within the same region. Based on the observed homology between the NH2-terminal module and the membrane proximal (WSXWS-containing) module of hIL-5R alpha we located this stretch of four amino acid residues (D55, D56, Y57 and E58) in the loop region that connects the C and D beta-strands on the proposed tertiary structure of the NH2-terminal module.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7628440      PMCID: PMC394406          DOI: 10.1002/j.1460-2075.1995.tb07345.x

Source DB:  PubMed          Journal:  EMBO J        ISSN: 0261-4189            Impact factor:   11.598


  34 in total

Review 1.  Interleukin-5, eosinophils, and disease.

Authors:  C J Sanderson
Journal:  Blood       Date:  1992-06-15       Impact factor: 22.113

2.  Site-directed mutagenesis of virtually any plasmid by eliminating a unique site.

Authors:  W P Deng; J A Nickoloff
Journal:  Anal Biochem       Date:  1992-01       Impact factor: 3.365

3.  Human growth hormone and extracellular domain of its receptor: crystal structure of the complex.

Authors:  A M de Vos; M Ultsch; A A Kossiakoff
Journal:  Science       Date:  1992-01-17       Impact factor: 47.728

4.  Interleukin-5, interleukin-3, and granulocyte-macrophage colony-stimulating factor cross-compete for binding to cell surface receptors on human eosinophils.

Authors:  A F Lopez; M A Vadas; J M Woodcock; S E Milton; A Lewis; M J Elliott; D Gillis; R Ireland; E Olwell; L S Park
Journal:  J Biol Chem       Date:  1991-12-25       Impact factor: 5.157

5.  Cloning of the low-affinity murine granulocyte-macrophage colony-stimulating factor receptor and reconstitution of a high-affinity receptor complex.

Authors:  L S Park; U Martin; R Sorensen; S Luhr; P J Morrissey; D Cosman; A Larsen
Journal:  Proc Natl Acad Sci U S A       Date:  1992-05-15       Impact factor: 11.205

6.  Molecular basis of the membrane-anchored and two soluble isoforms of the human interleukin 5 receptor alpha subunit.

Authors:  J Tavernier; T Tuypens; G Plaetinck; A Verhee; W Fiers; R Devos
Journal:  Proc Natl Acad Sci U S A       Date:  1992-08-01       Impact factor: 11.205

7.  Expression cloning of the human IL-3 receptor cDNA reveals a shared beta subunit for the human IL-3 and GM-CSF receptors.

Authors:  T Kitamura; N Sato; K Arai; A Miyajima
Journal:  Cell       Date:  1991-09-20       Impact factor: 41.582

8.  A human high affinity interleukin-5 receptor (IL5R) is composed of an IL5-specific alpha chain and a beta chain shared with the receptor for GM-CSF.

Authors:  J Tavernier; R Devos; S Cornelis; T Tuypens; J Van der Heyden; W Fiers; G Plaetinck
Journal:  Cell       Date:  1991-09-20       Impact factor: 41.582

9.  Two distinct functional high affinity receptors for mouse interleukin-3 (IL-3).

Authors:  T Hara; A Miyajima
Journal:  EMBO J       Date:  1992-05       Impact factor: 11.598

10.  Molecular cloning and expression of the human interleukin 5 receptor.

Authors:  Y Murata; S Takaki; M Migita; Y Kikuchi; A Tominaga; K Takatsu
Journal:  J Exp Med       Date:  1992-02-01       Impact factor: 14.307

View more
  6 in total

Review 1.  Interleukin-5, a therapeutic target in allergic inflammation.

Authors:  D P Huston; M M Huston; R R Dickason; M Martinez-Moczygemba
Journal:  Trans Am Clin Climatol Assoc       Date:  2000

2.  Two modes of beta-receptor recognition are mediated by distinct epitopes on mouse and human interleukin-3.

Authors:  Shamaruh Mirza; Jinglong Chen; Bin Wen; Cameron L Ewens; Jin Dai; James M Murphy; Ian G Young
Journal:  J Biol Chem       Date:  2010-05-14       Impact factor: 5.157

3.  High CD123 levels enhance proliferation in response to IL-3, but reduce chemotaxis by downregulating CXCR4 expression.

Authors:  Nicole L Wittwer; Gabriela Brumatti; Ceilidh Marchant; Jarrod J Sandow; Melanie K Pudney; Mara Dottore; Richard J D'Andrea; Angel F Lopez; Paul G Ekert; Hayley S Ramshaw
Journal:  Blood Adv       Date:  2017-06-20

4.  Engineering of a functional interleukin-5 monomer: a paradigm for redesigning helical bundle cytokines with therapeutic potential in allergy and asthma.

Authors:  R R Dickason; J D English; D P Huston
Journal:  J Mol Med (Berl)       Date:  1996-09       Impact factor: 4.599

5.  The role of interchain heterodisulfide formation in activation of the human common beta and mouse betaIL-3 receptors.

Authors:  Shamaruh Mirza; Jinglong Chen; James M Murphy; Ian G Young
Journal:  J Biol Chem       Date:  2010-06-01       Impact factor: 5.157

6.  Expression and in vitro properties of guinea pig IL-5: comparison to human and murine orthologs.

Authors:  C W Scott; C Budzilowicz; S J Hubbs; M Stein; C Sobotka-Briner; D E Wilkins
Journal:  Mediators Inflamm       Date:  2000       Impact factor: 4.711

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.